Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 4 October 2017, 09:49 HKT/SGT
Share:
    

Source: Eisai
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America

TOKYO, Oct 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America.

Under the terms of the agreement, Eisai Inc. grants Biotoscana an exclusive license to seek regulatory approvals and commercialize the anticancer agents Halaven and Lenvima, as well as antiepileptic agents Fycompa and Inovelon in Latin America. In Mexico, however, Eisai will retain the rights to, and conduct all activities for, Halaven and Lenvima. Eisai Inc. will supply Biotoscana with the products, for which it will receive compensation, and is also entitled to a one-time payment as well as milestone payments.

Biotoscana is a pharmaceutical company operating out of 10 countries in Latin America, where it is developing a strong portfolio that includes oncology products. As a result of granting Biotoscana these licenses, Eisai can swiftly expand access in Latin American markets for its innovative new drugs, and further contribute to patients in Latin America.

Eisai positions oncology and neurology as key therapeutic areas. By accelerating the development of its innovative new drugs in these areas and pursuing optimal business models to match regional characteristics, Eisai seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients and their families all over the world.

About Grupo Biotoscana Grupo

Biotoscana is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. Grupo Biotoscana is currently present throughout 10 Latin American countries (Argentina, Uruguay, Ecuador, Colombia, Chile, Paraguay, Brazil, Peru, Bolivia, and Mexico) where it operates under its companies Biotoscana, United Medical and LKM. Grupo Biotoscana's strong portfolio combines world-class licenses and proprietary products.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Oct 4, 2017 09:49 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Oct 13, 2017 09:48 HKT/SGT
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
Oct 11, 2017 11:48 HKT/SGT
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
Oct 3, 2017 14:11 HKT/SGT
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan
Sept 29, 2017 15:12 HKT/SGT
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting
Sept 27, 2017 12:25 HKT/SGT
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA
Sept 22, 2017 15:46 HKT/SGT
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
Sept 22, 2017 09:56 HKT/SGT
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC
Sept 19, 2017 09:01 HKT/SGT
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference
Sept 13, 2017 13:25 HKT/SGT
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
Sept 12, 2017 23:06 HKT/SGT
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: